Science Stories
As we deepen our commitment to oncology, we’re focused on bringing forward meaningful innovation for patients, especially those facing rare and aggressive cancers like H3 K27M-mutant diffuse midline glioma. With the FDA approval of the first treatment for this cancer, there is new hope for patients and families who are navigating this life-threatening disease.
Given the limited recognition of idiopathic hypersomnia, there is not substantial data on the burden of symptoms on those living with the disorder. Recent real-world evidence from a self-reported survey published in Nature and Science of Sleep reveals more insights around idiopathic hypersomnia symptoms and patients’ satisfaction with treatment regimens.
As a long-time leader in neuroscience, Jazz has held a longstanding commitment to provide therapies and support for patients living with serious, debilitating neurologic disorders, to help them reclaim their lives. Even though essential tremor (ET) is considered the most common movement disorder, affecting millions of people worldwide,1 there are limited treatment options for patients.
Post-traumatic stress disorder (PTSD) is a common psychiatric condition affecting approximately 10 million Americans that can result from actual or threatened traumatic events and experiences. Learn more about the prevalence of this complex psychiatric condition and Jazz’s efforts to address the significant unmet need for patients.